Last update :
19/11/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
valistab
valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Antiemetic   Fosaprepitant dimeglumine  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Emend Canada, United States of America
Fosaprepitant
IV-Emend Austria, Great Britain, Japan, Norway, Switzerland
References   injection   References : Fosaprepitant dimeglumine  
Type Publication
2295 Manufacturer Fosaprepitant (Emend®) - Summary of Product Characteristics
Merck Sharp Dohme 2013
3459 Journal Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
  Mentions Légales